PHVS: Oral deucrictibant matches injectable efficacy in HAE, with broad label and strong commercial prospects
Deucrictibant demonstrated high efficacy in phase III HAE trials, matching injectable therapies and offering oral convenience. Safety profile aligns with existing treatments, and regulatory filing is planned for next year. The product's broad mechanism and dual on-demand/prophylactic use position i…